Chronic heart failure is the leading cause of death in the world. With newer therapies, the burden of this disease has decreased; however, a significant number of patients remain refractive to existing therapies. Myocardial infarction often leads to ventricular remodeling and eventually contributes to heart failure. The Parachute TM (Cardiokinetix, Menlo Park, CA) is the first device designed for percutaneous ventricular restoration therapy, which reduces left ventricular volume and minimizes the risk of open surgical procedures. For the first time, we report a case of explantation of the Parachute ventricular partitioning device and transition to a HeartMate II TM left ventricular assist device and the surgical considerations for a successful outcome. C hronic heart failure (HF) patients with previous anterolateral myocardial infarction resulting in anteroapical regional wall motion abnormality have been treated with the Cardiokinetix Parachute ventricular partitioning device (VPD), which is deployed percutaneously in the left ventricular (LV) cavity to the dysfunctional region ( 1 ) . While the data from the trial demonstrate improved outcomes, a small percentage of patients continue to deteriorate symptomatically ( 2 , 3 ) . Th is necessitates consideration for advanced surgical therapies for HF, including heart transplantation and longterm mechanical circulatory support ( 2 , 3 ) . Th e presence of a VPD and the static LV chamber pose surgical challenges during placement of long-term devices. We report our experience in the successful removal of the VPD and implantation of a left ventricular assist device (LVAD).
CASE REPORT
A 57-year-old woman with a longstanding history of HF due to morbid obesity was not considered to be a candidate for heart transplantation. She also had hypertension, hyperlipidemia, chronic obstructive pulmonary disease, and depression. She presented with severe chest pain, fatigue, and dizziness and a prior history of numerous percutaneous interventions on the coronary vasculature. In 2009, due to progression of HF, the patient had successful VPD placement. Postimplant, her ejection fraction improved from 15% to 25% with subjective improvement of HF symptoms. However, 24 months after VPD placement, she presented in New A year after the LVAD was placed, it was explanted because it clotted off . Th e patient survived this incident. Interestingly, she did well for a period of time, but in 2014, she had multiple admissions for HF and was once again screened for the Parachute USA trial. As there were no exclusion criteria for prior LVAD, nor prior Parachute implantations, she was reenrolled (phase 3), and a Parachute device was placed successfully. Th is patient had the fi rst-ever reimplant of a VPD. She has subsequently done well and is presently listed in class 2 HF.
DISCUSSION
Th e Parachute device is made of a self-expanding nitinol frame, an expanded polytetrafl uoroethylene impermeable occlusive membrane, and a polymer foot. Th e Parachute system encompasses the device, balloon, and a delivery system consisting of the catheter and dilator ( 4 ) . Th e frame has a conical shape, which has 16 struts, the tips of which have anchors. Th e anchors stabilize the device in the myocardium. However, these struts have the potential to be fi rmly adherent to the myocardium after deployment in the LV chamber. Moreover, it is conceivable that the excluded portion of the LV chamber between the VPD and the scarred area of the LV wall harbors a static column of blood, which could lead to thrombus formation ( 4 ) . Th e foot is radio-opaque and aids visualization for proper placement of the device under fl uoroscopy ( 3 ) .
A median sternotomy is performed and the patient is fully heparinized. Ascending aortic cannulation is carried April 2016 Surgical considerations for the explantation of the Parachute left ventricular partitioning device out by placing an Embol-X (Edwards LifeSciences, Irvine, CA) aortic cannula in the ascending aorta and a dual-stage venous cannula in the right atrium. The size of the ascending aorta is measured and the appropriately sized specialized net is selected and placed through the side port of the aortic cannula and deployed in the ascending aorta. The power source of the LVAD is disconnected and the patient is immediately placed on a full cardiopulmonary bypass circuit. The deployment of the appropriately sized net in the ascending aorta facilitates the capture of any particulate embolic debris that may potentially be dislodged from the LV cavity due to altered flow dynamics in the chamber secondary to discontinuation of LVAD support and initiation of cardiopulmonary bypass. The aorta is cross-clamped. After the patient is placed in a steep Trendelenburg position, the left ventricle is brought into the midline and the apex is cored. Care should be taken to ensure that in the process of LV wall coring, the membranous portion of the VPD is not damaged by the coring device and hence the problem of distal embolization is avoided.
It is imperative to perform a thorough evaluation of the LV chamber excluded by the VPD. Th is is the region of the LV chamber bounded by the LV scarred akinetic portion and the outer surface of the VPD. Th e potential for clot formation in this region is signifi cant due to factors including the akinetic nature of the chamber walls and the absence of washout in the space excluded by the VPD ( Figure ) . Th e clot is carefully evacuated through the cored out LV apex.
Th e self-expanding nitinol frame of the VPD is tipped with pointed barbs which, after initial deployment, are fi rmly embedded in the LV free wall and septum with development of fi brous tissue around the end regions of the nitinol frame. A gentle inward pressure on each strut of the nitinol frame toward its center dislodges the struts from the LV points of embedment. Subsequently, the VPD is explanted through the LV apex. Th e outside of the LV wall and ventricular septum are carefully inspected to ensure the absence of partial or full thickness lacerations. Th e LVAD is then implanted, and the patient is gradually weaned off cardiopulmonary bypass and placed on LVAD support. Prior to decannulation, the net deployed through the aortic cannula is removed and evaluated for the presence of particulate debris. 
